Back to top

Is ABIOMED (ABMD) Outperforming Other Medical Stocks This Year?

Read MoreHide Full Article

Investors focused on the Medical space have likely heard of ABIOMED (ABMD - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.

ABIOMED is a member of our Medical group, which includes 843 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. ABMD is currently sporting a Zacks Rank of #2 (Buy).

The Zacks Consensus Estimate for ABMD's full-year earnings has moved 3.35% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.

Based on the latest available data, ABMD has gained about 78.87% so far this year. In comparison, Medical companies have returned an average of 4.91%. This means that ABIOMED is performing better than its sector in terms of year-to-date returns.

To break things down more, ABMD belongs to the Medical - Instruments industry, a group that includes 93 individual companies and currently sits at #71 in the Zacks Industry Rank. On average, this group has gained an average of 17.90% so far this year, meaning that ABMD is performing better in terms of year-to-date returns.

Investors in the Medical sector will want to keep a close eye on ABMD as it attempts to continue its solid performance.




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


ABIOMED, Inc. (ABMD) - free report >>

More from Zacks Tale of the Tape

You May Like

Published in